Literature DB >> 10398256

Cutaneous mosaicism of lethal mutations.

H Hamm1.   

Abstract

The concept of autosomal lethal genes surviving only in a mosaic state was proposed by Happle to explain the genetic basis of several syndromes characterized by (almost always) sporadic occurrence, distribution of lesions in a scattered or asymmetrical pattern, variable extent of involvement, lack of diffuse involvement of entire organs, and equal sex ratio. The mosaic may either arise from a gametic half-chromatid mutation or from an early postzygotic mutation. The purpose of this article is to review current knowledge of the genetics and cutaneous manifestations of some of the birth defects to which the lethal gene concept is thought to apply: the Schimmelpenning (Feuerstein-Mims) syndrome, Proteus syndrome, encephalocraniocutaneous lipomatosis, Sturge-Weber and Klippel-Trenaunay syndrome, cutis marmorata teleangiectatica congenita (van Lohuizen syndrome), and neurocutaneous melanosis. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10398256     DOI: 10.1002/(sici)1096-8628(19990806)85:4<342::aid-ajmg6>3.0.co;2-8

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  14 in total

1.  Twenty classic hand radiographs that lead to diagnosis.

Authors:  Govind B Chavhan; Elka Miller; Erika H Mann; Stephen F Miller
Journal:  Pediatr Radiol       Date:  2010-02-04

2.  Are patients with encephalocraniocutaneous lipomatosis at increased risk of developing low-grade gliomas?

Authors:  Elvis Terci Valera; María Sol Brassesco; Carlos Alberto Scrideli; Marcus Vinicius de Castro Barros; Antonio Carlos Santos; Ricardo Santos Oliveira; Hélio Rubens Machado; Luiz Gonzaga Tone
Journal:  Childs Nerv Syst       Date:  2011-10-08       Impact factor: 1.475

3.  A Filipino male with encephalocraniocutaneous lipomatosis (Haberland's syndrome).

Authors:  Iris Alessandra S Pardo; Marie Eleanore O Nicolas
Journal:  J Dermatol Case Rep       Date:  2013-06-30

Review 4.  In vivo reversion to normal of inherited mutations in humans.

Authors:  R Hirschhorn
Journal:  J Med Genet       Date:  2003-10       Impact factor: 6.318

5.  Low-grade astrocytoma in a child with encephalocraniocutaneous lipomatosis.

Authors:  María Sol Brassesco; Elvis Terci Valera; Aline Paixão Becker; Angel Mauricio Castro-Gamero; André de Aboim Machado; Antônio Carlos Santos; Carlos Alberto Scrideli; Ricardo Santos Oliveira; Hélio Rubens Machado; Luiz Gonzaga Tone
Journal:  J Neurooncol       Date:  2009-08-04       Impact factor: 4.130

6.  Mosaic Activating Mutations in FGFR1 Cause Encephalocraniocutaneous Lipomatosis.

Authors:  James T Bennett; Tiong Yang Tan; Diana Alcantara; Martine Tétrault; Andrew E Timms; Dana Jensen; Sarah Collins; Malgorzata J M Nowaczyk; Marjorie J Lindhurst; Katherine M Christensen; Stephen R Braddock; Heather Brandling-Bennett; Raoul C M Hennekam; Brian Chung; Anna Lehman; John Su; SuYuen Ng; David J Amor; Jacek Majewski; Les G Biesecker; Kym M Boycott; William B Dobyns; Mark O'Driscoll; Ute Moog; Laura M McDonell
Journal:  Am J Hum Genet       Date:  2016-03-03       Impact factor: 11.025

7.  HRAS mutations in bladder cancer at an early age and the possible association with the Costello Syndrome.

Authors:  Willemien Beukers; Aleksander Hercegovac; Ellen C Zwarthoff
Journal:  Eur J Hum Genet       Date:  2013-10-30       Impact factor: 4.246

8.  A case of concurrent proteus syndrome and hemophilia a.

Authors:  Mozhgan Hashemieh; Bahar Mansoori; Reza Tavakoli; Koroush Sheibani
Journal:  Iran J Pediatr       Date:  2012-06       Impact factor: 0.364

Review 9.  Cutaneous mosaicisms: concepts, patterns and classifications.

Authors:  Samara Silva Kouzak; Marcela Sena Teixeira Mendes; Izelda Maria Carvalho Costa
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896

10.  KRAS G12D mosaic mutation in a Chinese linear nevus sebaceous syndrome infant.

Authors:  Huijun Wang; Yanyan Qian; Bingbing Wu; Ping Zhang; Wenhao Zhou
Journal:  BMC Med Genet       Date:  2015-10-31       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.